Journal: Cancer cell international

Article Title: High expression of prolactin receptor is associated with cell survival in cervical cancer cells.

doi: 10.1186/1475-2867-13-103

Figure Lengend Snippet: Figure 1 PRLR expression in human cervical cancer cells. SiHa, C-33A, HeLa (Cervical cancer cells) and control cells MCF-7, T-47D (breast cancer), HaCaT (Inmortalized human keratinocytes) were cultured in DMEM or RPMI medium containing 10% FBS. A) PRLR protein was determined by western blot using a specific antibody against the PRLR, PRLR proteins were identified by their size. B) Demonstration of the arbitrary optical density measurements from Western immunoblots assessing PRLR levels. C) The cells grown on coverslips were fixed, and the localization of PRLR (green) was observed by inmunocitochemistry using a secondary antibody conjugated with Alexa fluor 488 and DAPI stain (blue) to visualize the presence of cells. Magnification 10 x. D) Relative expression of PRLR mRNA was measure by quantitative RT-PCR.

Article Snippet: Growth medium was replaced with serum free medium supplemented with 10% charcoal striped serum (CSS) before dosing with PRL 200ng/ml (L7009 Sigma), PRLR neutralizing antibody (MAB1167 R&D systems) or PRL antibody (6F11 QED Bioscience) for 3 or 5 days.

Techniques: Expressing, Control, Cell Culture, Western Blot, Staining, Quantitative RT-PCR

Journal: Cancer cell international

Article Title: High expression of prolactin receptor is associated with cell survival in cervical cancer cells.

doi: 10.1186/1475-2867-13-103

Figure Lengend Snippet: Figure 3 Effects of PRL and PRL or PRLR blocking antibodies on proliferation of cervical cancer cells. Effects on metabolic activity after the incubation with PRL (200 ng/ml), PRL-AB (200 ng/ml) or PRLR-AB (2.5 μg) for 3 or 5 days in HeLa, SiHa, C-33A (A, B, C) and control cells MCF-7, T-47D and HaCaT (D, E, F). Graphs show experiments performed in triplicate, which are repeated at least three times. *p<.05.

Article Snippet: Growth medium was replaced with serum free medium supplemented with 10% charcoal striped serum (CSS) before dosing with PRL 200ng/ml (L7009 Sigma), PRLR neutralizing antibody (MAB1167 R&D systems) or PRL antibody (6F11 QED Bioscience) for 3 or 5 days.

Techniques: Blocking Assay, Activity Assay, Incubation, Control